Prediabetes: what do we know about it today?


DOI: https://dx.doi.org/10.18565/therapy.2020.8.168-173

Demidova T.Yu., Kishkovich Yu.S.

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Moscow
Prediabetes is an early disorder of carbohydrate metabolism. In itself, a mild condition, often not manifesting clinically, has enormous consequences in the case of non-intervention or delayed response. Today we are talking not only about the glycemic status of patients, glycemic variability, but mainly about the effect of hyperglycemia on cardiovascular risks, about possible complications that could be delayed or prevented. Rational selection of risk groups, early diagnosis, timely correction of lifestyle, rational pharmacotherapy are the basis for the prevention and treatment of pre-diabetes conditions. In turn, knowledge of epidemiology, understanding of pathogenesis, further study of the influence of hyperglycemia, standardization of laboratory diagnostics – all this is necessary to assess the scale of the problem and find optimal solutions.
Keywords: impaired fasting glucose, oral glucose tolerance test, impaired glucose tolerance, prediabetes, oxidative stress
Read entire article

Literature


  1. IDF Diabetes Atlas. 9th edition. 2019. URL: https://www.diabetesatlas.org/upload/resources/2019/IDF_Atlas_9th_Edition_2019.pdf (date of access – 01.11.2020).

  2. Дедов И.И., Шестакова М.В., Майоров А.Ю. с соавт. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 9-й выпуск. Сахарный диабет. 2019; S1–1: 1–144. [Dedov I.I., Shestakova M.V., Mayorov A.Y. et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition. Sakharniy diabet. 2019; S1–1: 1–144 (In Russ.)].

  3. American Diabetes Association. 3. Prevention or delay of type 2 diabetes: standards of medical care in diabetes-2020. Diabetes Care. 2020; 43(Suppl 1): S32–S36. doi: 10.2337/dc20-S003.

  4. Рекомендации по диабету, предиабету и сердечно-сосудистым заболеваниям. EASD/ESC. Российский кардиологический журнал. 2014; 3: 7–61. [ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Rossiyskiy kardiologicheskiy zhurnal. 2014; 3: 7–61 (In Russ.)].

  5. Makaroff L.E. The need for international consensus on prediabetes. Lancet Diabetes Endocrinol. 2017; 5(1): 5–7. doi:10.1016/S2213-8587(16)30328-X.

  6. Zhang X., Gregg E.W., Williamson D.F. et al. A1C level and future risk of diabetes: a systematic review. Diabetes Care. 2010; 33(7): 1665–73. doi: 10.2337/dc09-1939.

  7. Cai X., Zhang Y., Li M. et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ. 2020; 370: m2297. doi: 10.1136/bmj.m2297.

  8. Sen K., Mukherjee A.K., Dharchowdhury L., Chatterjee A. A study to find out the proportion of prediabetes in patients with acute coronary syndrome in a medical college of Kolkata. J Indian Med Assoc. 2008; 106(12): 776–78.

  9. Di Pino A., Mangiafico S., Urbano F. et al. HbA1c identifies subjects with prediabetes and subclinical left ventricular diastolic dysfunction. J Clin Endocrinol Metab. 2017; 102(10): 3756–64. doi: 10.1210/jc.2017-00954.

  10. Luc K., Schramm-Luc A., Guzik T.J., Mikolajczyk T.P. Oxidative stress and inflammatory markers in prediabetes and diabetes. J Physiol Pharmacol. 2019; 70(6). doi: 10.26402/jpp.2019.6.01.

  11. Maschirow L., Khalaf K., Al-Aubaidy H.A., Jelinek H.F. Inflammation, coagulation, endothelial dysfunction and oxidative stress in prediabetes - biomarkers as a possible tool for early disease detection for rural screening. Clin Biochem. 2015; 48(9): 581–85. doi: 10.1016/j.clinbiochem.2015.02.015.

  12. Al-Aubaidy H.A., Jelinek H.F. Oxidative stress and triglycerides as predictors of subclinical atherosclerosis in prediabetes. Redox Rep. 2014; 19(2): 87–91. doi: 10.1179/1351000213Y.0000000080.

  13. Brahimaj A., Ligthart S., Ghanbari M. et al. Novel inflammatory markers for incident pre-diabetes and type 2 diabetes: the Rotterdam Study. Eur J Epidemiol. 2017; 32(3): 217–26. doi: 10.1007/s10654-017-0236-0.

  14. Grossmann V., Schmitt V.H., Zeller T. et al. Profile of the immune and inflammatory response in individuals with prediabetes and type 2 diabetes. Diabetes Care. 2015; 38(7): 1356–64. doi: 10.2337/dc14-3008.

  15. Tuomilehto J., Lindstrom J., Eriksson J.G. et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344(18): 1343–50. doi: 10.1056/NEJM200105033441801.

  16. Li G., Zhang P., Wang J. et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2014; 2(6): 474–80. doi: 10.1016/S2213-8587(14)70057-9.

  17. Gong Q., Zhang P., Wang J. et al. Da Qing Diabetes Prevention Study Group. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019; 7(6): 452–61. doi: 10.1016/S2213-8587(19)30093-2.

  18. Knowler W.C., Barrett-Connor E., Fowler S.E. et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346(6): 393–403. doi: 10.1056/NEJMoa012512.

  19. Yuan X., Dai X., Liu L. et al. Comparing the effects of 6 months aerobic exercise and resistance training on metabolic control and β-cell function in Chinese patients with prediabetes: A multicenter randomized controlled trial. J Diabetes. 2020; 12(1): 25–37. doi: 10.1111/1753-0407.12955.

  20. Демидова И.Ю., Боева В.В., Завьялов А.Н. Отдаленные результаты медикаментозной коррекции предиабета. Эндокринология. Новости. Мнения. Обучение. 2020; 1: 27–34. [Demidova I.Yu., Boeva V.V., Zavyalov A.N. Long-term results of pharmacological correction of prediabetes. Endokrinologiya. Novosti. Mneniya. Obuchenie. 2020; 1: 27–34 (In Russ.)]. doi: 10.33029/2304-9529-2020-9-1-27-34

  21. Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015; 3(11): 866–75. doi: 10.1016/S2213-8587(15)00291-0.

  22. Liu C., Foti K., Grams M.E. et al. Trends in self-reported prediabetes and metformin use in the USA: NHANES 2005–2014. J Gen Intern Med. 2020; 35(1): 95–101. doi: 10.1007/s11606-019-05398-5.


About the Autors

Tatyana Yu. Demidova, MD, professor, head of the Department of endocrinology, faculty of general medicine of N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 109263, Moscow, 4/1 Shkuleva Str. E-mail: t.y.demidova@gmail.com. ORCID: 0000-0001-6385-540X
Yulia S. Kishkovich, assistant of the Department of endocrinology, faculty of general medicine of N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, Moscow, 1 Ostrovityaninova Str. E-mail: maximovajuly22@gmail.com


Similar Articles

Back to Content

Бионика Медиа